These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17442100)

  • 1. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
    Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
    Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
    Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
    Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and efficacy of anti-Aspergillus therapy in patients with hematological malignancies and invasive aspergillosis].
    Li Y; Gao L; Wang LL; Wang QS; Li HH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1289-93. PubMed ID: 22040990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
    Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
    Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
    Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful antifungal combination therapy with voriconazole and caspofungin.
    Schuster F; Moelter C; Schmid I; Graubner UB; Kammer B; Belohradsky BH; Führer M
    Pediatr Blood Cancer; 2005 Jun; 44(7):682-5. PubMed ID: 15700260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study.
    Rubio PM; Sevilla J; González-Vicent M; Lassaletta A; Cuenca-Estrella M; Díaz MA; Riesco S; Madero L
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):642-6. PubMed ID: 19684521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
    Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
    Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
    Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
    J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
    Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
    Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
    Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
    Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
    Klont RR; Mennink-Kersten MA; Ruegebrink D; Rijs AJ; Blijlevens NM; Donnelly JP; Verweij PE
    Clin Infect Dis; 2006 Aug; 43(3):e23-5. PubMed ID: 16804836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
    Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
    J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.